GLOBAL LIVER INSTITUTE
Global Liver Institute (GLI) celebrates the expansion of treatment options for patients with primary biliary cholangitis (PBC) after the U.S. Food and Drug Administration decided to provide accelerated approval of Gilead Science’s seladelpar (Livdelzi®) for primary biliary cholangitis (PBC).
Congress is entering the August recess period. Nevertheless, patients are increasingly signaling to policymakers their frustration related to coverage challenges and over-zealous utilization management practices such as non-medical switching and other barriers to care. And appropriations bills are out for FY 2025!
The recent FDA approval of resmetirom, which offers hope for those with moderate-to-advanced liver scarring, marks a breakthrough in treatment.
Thank you for reading Liver Cancer News! Liver cancer is associated with low five-year survival rates, often due to late-stage diagnosis of the disease.
Ipsen Pharmaceuticals has just shared exciting news for rare liver disease patients with cholestasis.
Trauma-informed, patient-led consultations to build trust and enhance medical care are important to clinical care for liver health, Dr. Julia Wattacheril, Director of the MASLD Program at Columbia’s Center for Liver Disease and Transplantation, has emphasized.
Based on our shared knowledge and experience, Global Liver Institute and National Alliance for Caregiving are proud to collaborate in providing recommendations to CMS and the Centers for Medicare and Medicaid Innovation (CMMI) that we believe will improve the proposed Increasing Organ Transplant Access (IOTA) Model
The House Ways and Means Committee marked up obesity legislation, moving the ball forward for Congress to act on coverage for Medicare beneficiaries. GLI solicits signatures on a petition to insurers to provide access to NASH/MASH treatment.
We are honored to have had the opportunity to represent the rare liver diseases community at the Alpha-1 Foundation National Conference in Miami, Florida. The weekend was filled with transformative research and thought-provoking conversations.
A new AI-driven blood test has been developed to improve the detection of liver cancer. Currently, up to 60% of liver cancers are not diagnosed until advanced stages, with a survival rate of just 20%.
Global Liver Institute Supports the U.S. House Ways and Means Committee's Markup of Legislation to Expand Obesity Care CoverageGlobal Liver Institute strongly supports the amendment to be considered...
Dr. Kelly Brownell, Dean Emeritus of the Sanford School of Public Policy at Duke University, has over 35 years of experience studying food systems and obesity. After initially focusing on obesity treatments, he found that weight loss often led to rapid regain, suggesting a harmful metabolic change.
